Uwell Biopharma, Inc. (TPEX:7902)
Taiwan
· Delayed Price · Currency is TWD 46.95
+1.00 (2.18%)
At close: Apr 27, 2026
Uwell Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 0.45 | 0.45 | - | - | - | - | Upgrade
|
| Cost of Revenue | 0.15 | 0.15 | - | - | - | - | Upgrade
|
| Gross Profit | 0.3 | 0.3 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 11.07 | 11.09 | 11.47 | 11.52 | 14.19 | 15.37 | Upgrade
|
| Research & Development | 44.67 | 32.63 | 37.18 | 38.51 | 35.45 | 24.28 | Upgrade
|
| Operating Expenses | 55.74 | 43.72 | 48.64 | 50.03 | 49.64 | 39.65 | Upgrade
|
| Operating Income | -55.44 | -43.42 | -48.64 | -50.03 | -49.64 | -39.65 | Upgrade
|
| Interest Expense | -0.17 | -0.21 | -0.22 | -0.28 | -0.42 | -0.34 | Upgrade
|
| Interest & Investment Income | 0.75 | 0.83 | 0.62 | 0.26 | 0.05 | 0.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 1.92 | 3.08 | 8.58 | 0.01 | 0.29 | Upgrade
|
| EBT Excluding Unusual Items | -54.86 | -40.87 | -45.17 | -41.47 | -49.99 | -39.48 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.03 | Upgrade
|
| Pretax Income | -54.86 | -40.87 | -45.17 | -41.47 | -49.99 | -39.45 | Upgrade
|
| Net Income | -54.86 | -40.87 | -45.17 | -41.47 | -49.99 | -39.45 | Upgrade
|
| Net Income to Common | -54.86 | -40.87 | -45.17 | -41.47 | -49.99 | -39.45 | Upgrade
|
| Shares Outstanding (Basic) | 117 | 117 | 89 | 57 | 24 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 117 | 117 | 89 | 57 | 24 | 21 | Upgrade
|
| Shares Change (YoY) | 105.26% | 31.62% | 55.95% | 141.86% | 11.16% | 28.48% | Upgrade
|
| EPS (Basic) | -0.47 | -0.35 | -0.51 | -0.73 | -2.12 | -1.86 | Upgrade
|
| EPS (Diluted) | -0.47 | -0.35 | -0.51 | -0.73 | -2.12 | -1.86 | Upgrade
|
| Free Cash Flow | -40.38 | -32.38 | -42.64 | -35.86 | -43.65 | -54.18 | Upgrade
|
| Free Cash Flow Per Share | -0.34 | -0.28 | -0.48 | -0.63 | -1.85 | -2.56 | Upgrade
|
| Gross Margin | 66.89% | 66.89% | - | - | - | - | Upgrade
|
| Operating Margin | -12320.44% | -9648.00% | - | - | - | - | Upgrade
|
| Profit Margin | -12190.89% | -9082.67% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -8972.67% | -7196.22% | - | - | - | - | Upgrade
|
| EBITDA | -52.36 | -40.32 | -45.53 | -47.15 | -47.57 | -39.33 | Upgrade
|
| D&A For EBITDA | 3.09 | 3.1 | 3.12 | 2.88 | 2.07 | 0.32 | Upgrade
|
| EBIT | -55.44 | -43.42 | -48.64 | -50.03 | -49.64 | -39.65 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.